Ghoneim et al. (10) demonstrated that de novo methylation-mediated by DNMT3a in an effector CD8+ T cell response to a tumor challenge is critical for establishing T cell exhaustion and that DAC may function by reversing exhaustion-associated de novo methylation programs in CD8+ T cells, therefore enhancing the T cell expansion during ICB treatment. Here, DNMT3A is linked to neoplasm.